Stock Movers: Eli Lilly's Obesity Drug, Gemini Space Station's Exchange Approval, Oracle's Cloud Sales Forecast

Eli Lilly's Obesity Drug Success

• 💡 Eli Lilly saw its stock rise as an experimental obesity shot demonstrated patients losing nearly 23% of their body weight in late-stage studies.
• 🎯 This drug, potentially the most potent weight-loss medicine yet, also showed a 62% reduction in knee pain for participants.
• 📈 The obesity market is projected to reach $100 billion by 2030, highlighting the significant potential for such treatments.
• ⚠️ Despite intense competition, Eli Lilly (LLY) is focused on developing highly effective drugs, with Zepbound already being popular.

Gemini Space Station's Regulatory Approval

• 🚀 Gemini Space Station (GEMI) surged 25% after receiving approval from the CFTC for its derivatives exchange application.
• 🧩 This approval allows the company to enter the rapidly growing prediction markets field, enabling US customers to trade event contracts.
• 💬 While often associated with crypto, Gemini is expanding into new financial sectors, mirroring a trend among crypto-native firms.
• ⚠️ A notable sentiment indicator is that 42% of the float is short on Gemini Space Station, suggesting some negative investor outlook despite the stock's rise.

Oracle's Cloud Sales Concerns

• 📉 Oracle experienced a significant stock drop, its steepest in 24 years, following a disappointing 3Q forecast.
• ☁️ The company's cloud sales growth fell short of analyst estimates, raising concerns about its ability to convert a large backlog into revenue due to supply constraints.
• 📊 Oracle had previously projected substantial capital expenditures and annual revenue, but the latest report has tempered investor enthusiasm.
• 📈 This marks a reversal for Oracle (ORCL), which had enjoyed a strong rally earlier in the year, with its co-founder Larry Ellison briefly becoming the world's richest man.